Enovis Corporation (ENOV)

Market Cap	1.31B
Revenue (ttm)	2.23B
Net Income (ttm)	-1.37B
Shares Out	57.19M
EPS (ttm)	-24.09
PE Ratio	n/a
Forward PE	7.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87,002
Open	23.00
Previous Close	23.01
Day's Range	22.53 - 23.27
52-Week Range	22.50 - 49.38
Beta	1.65
Analysts	Strong Buy
Price Target	48.13 (+109.53%)
Earnings Date	Feb 26, 2026

About ENOV

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company’s Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management,...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 8, 2008
• Employees: 7,367
• Stock Exchange: NYSE
• Ticker Symbol: ENOV
• Website: https://www.enovis.com

Financial Performance

In 2024, Enovis's revenue was $2.11 billion, an increase of 23.46% compared to the previous year's $1.71 billion. Losses were -$825.49 million, 2381.9% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for ENOV stock is "Strong Buy." The 12-month stock price target is $48.13, which is an increase of 109.53% from the latest price.

Price Target

$48.13

(109.53% upside)

Analyst Consensus: Strong Buy